Mirae Asset Global Investments Co., Ltd. Krystal Biotech, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $20 Billion
- Q2 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 853 shares of KRYS stock, worth $161,438. This represents 0.0% of its overall portfolio holdings.
Number of Shares
853
Previous 12,001
92.89%
Holding current value
$161,438
Previous $2.14 Million
92.69%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding KRYS
# of Institutions
266Shares Held
25MCall Options Held
270KPut Options Held
172K-
Black Rock Inc. New York, NY3.95MShares$747 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.87MShares$543 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.43MShares$460 Million6.1% of portfolio
-
State Street Corp Boston, MA1.33MShares$252 Million0.01% of portfolio
-
Redmile Group, LLC San Francisco, CA1.02MShares$193 Million12.22% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.86B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...